Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Görögország2. fázis

A Double-Blind, Placebo-Controlled, Crossover Pilot Study of the Efficacy and Safety of Fluasterone Buccal Tablet in the Control of Hyperglycemia in Adults with Endogenous Cushing’s Syndrome

A legfontosabb adatok

Ki végzi
Sterotherapeutics LLC
Hol
Athens, Efkarpia, Heraklion, Larissa, Patras, Thessaloniki és Νikaia (Görögország)Mind a 10 helyszín megnézése
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
24 fő, tervezett
Kezdés
2025. máj. 2.
Várható befejezés
2027. dec. 31.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. szeptember 14.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with endogenous Cushing's syndrome (the body makes too much cortisol) who also have high blood sugar. This means impaired glucose tolerance or type 2 diabetes.

Életkor
18 to 75 years
Nem
Men and women
A betegség stádiuma
Possible endogenous Cushing syndrome checked in the last 12 months, ACTH-dependent or ACTH-independent. People must also have impaired glucose tolerance or type 2 diabetes with HbA1c <9% (75 mmol/mol) in the last three months.
Korábbi kezelés
Doses of any blood sugar medicine must have been stable for 60 days. Glucocorticoid replacement after Cushing's surgery must have stopped at least one week, or 5 half-lives, before screening. No mifepristone in the last 2 months.
Biomarker vagy leletérték
2 of 3 cortisol tests must be abnormal: 24-hour urine free cortisol above the upper limit of normal on two occasions, blood cortisol over 1.8 µg/dL (50 nmol/L) after the 1-mg dexamethasone test, or a raised midnight cortisol. In the oGTT, 2-hour plasma glucose ≥140 mg/dl (7,8 mmol/L) and <200 mg/dl (11,1 mmol/L).

A részvétel fő kizáró okai

  • Acute or unstable illness, or active cancer (except localized basal cell skin cancer and adrenal carcinoma)
  • Serious heart problems, or a heart attack within 12 months
  • Too much cortisol from medicines or another outside source
  • Pregnant or breastfeeding women
  • G6PD deficiency, or allergy to fluasterone or DHEA

A regiszter feltételei, szó szerint

Mind a 31 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female patients aged 18 to 75 years, inclusive
  • Patient has read and signed the IRB/ Institutional Ethics Committee (IEC) approved ICF before screening procedures are undertaken
  • Has been evaluated within the previous 12 months for the possibility of endogenous Cushing syndrome (caused by either ACTH-dependent or ACTH-independent etiologies), meaning to fulfil 2 out of the 3 following criteria as per European guidelines:  an elevated 24-hour urine free cortisol (UFC), above the upper limit of normal (ULN) as per the reference range of the laboratory assay, on two occasions, or  an abnormal response to an overnight 1-mg dexamethasone suppression test (DST), i.e., an elevated blood cortisol over 1.8 µg/dL (50 nmol/L) measured between 8 AM and 9 AM, after a 1-mg dexamethasone oral administration between 11 PM and 12 PM the previous night,  or an abnormal midnight serum or salivary cortisol levels prior to initiation of study treatment, meaning:  for “sleeping” midnight serum cortisol to be greater than 1.8 μg/dl (>50 nmol/liter), OR for “awake” midnight serum cortisol to be greater than 7.5 μg/dl (>207 nmol/liter), or  for late-night salivary cortisol (LNSC) to be above the ULN as per the reference range of the laboratory assay
  • Has been diagnosed with impaired glucose tolerance (IGT), i.e., 2-hour plasma glucose ≥140 mg/dl and <200 mg/dl during an oGTT, or type 2 diabetes mellitus according to EASD/ADA guidelines, with HbA1c <9% during the last three months
  • If the patient receives treatment(s) for hyperglycemia, the dose(s) must have been stable for the 60 days prior to the Pre-Screening Visit
  • If the patient has received post-operative glucocorticoid replacement therapy following surgery for Cushing’s Disease, he/ she must have discontinued such therapy for at least one week, or 5 half-lives, whichever is longer, prior to Screening Visit #1

Ki nem vehet részt

  • Has a history of alcohol or drug abuse within 6 months prior to Screening Visit #1
  • Has received treatment with mifepristone within the 2 months period prior to Screening Visit #1
  • Is receiving other medicinal products interfering with cortisol production and/or metabolism
  • Is a pregnant woman or woman of childbearing potential (WOCBP) who is receiving oral contraceptive pills or is unable or unwilling to utilize appropriate methods of contraception during the study
  • Has positive urine drug screen for drugs of abuse, excepting prescribed medications
  • Has received treatment with an investigational product (drug, biologic agent, and/or device) within 30 days or 5 half-lives, whichever is longer at the time of Screening Visit #1
  • Has received pituitary radiation (stereotactic radiosurgery) within 2 years of Screening Visit #1 or conventional radiation within 3 years of Screening Visit #1
  • Has an acute or unstable medical condition
  • Has history of currently active malignancy involving any organ system (other than localized basal cell carcinoma of the skin and adrenal carcinoma)
  • Has a history of congestive heart failure, unstable angina, sustained ventricular tachycardia, clinically significant bradycardia, advanced heart block, or acute myocardial infarction within 12 months of Screening Visit #1
  • Has uncontrolled hypertension defined as >170/110 mmHg
  • Has a history of an allergic reaction to fluasterone or DHEA
  • Has a non-endogenous source of hypercortisolism such as factitious hypercortisolemia (exogenous source of glucocorticoid, iatrogenic Cushing’s syndrome), factitious or therapeutic use of ACTH
  • Has 2-hour plasma glucose <140 mg/dl in oGTT at Screening Visit #1, unless under stable treatment for hyperglycemia for at least 2 months prior to Screening visit #1 (lowest acceptable 2-hour plasma glucose in oGTT at Screening visit #1 is 110 mg/dL and HbA1c is 6.0 %)
  • Has HbA1c >9% within the last 3 months
  • Has clinical laboratory results for hematology at Screening Visit #1 that includes one or more of the following: hemoglobin <9 g/dL, total WBC <3000 cells/mm3, ANC <1500 cells/mm3, platelet count <100K /mm3
  • Has clinical laboratory results for chemistry at Screening Visit #1 that includes one or more of the following: ALT >5 x ULN, AST >5 x ULN, bilirubin >2 x ULN, estimated creatinine clearance <50 mL/min (by Cockroft-Gault equation)
  • Has hypokalemia (serum potassium < 3.0 mg/dL) at Screening Visit #1
  • Has electrocardiogram (ECG) at Screening Visit #1 that shows prolongation of QTcF interval >450 msec in males or >470 msec in females, or any clinically significant dysrhythmia
  • Has uncontrolled hypothyroidism or hyperthyroidism
  • Is a patient who, in the opinion of the Investigator, is not able to comply with study requirements
  • Has G6PD deficiency
  • Is a male subject with female partner of childbearing potential, who is unwilling to use a condom and his partner to use an additional form of adequate contraception
  • Is a female who is breast feeding
  • Has non-neoplastic hypercortisolism

Ez a vizsgálat jelenleg itt érhető el: Görögország.

  • Evangelismos S AAthens, GörögországRésztvevőt keres
  • General Hospital Of Athens Korgialenio Benakio H R CAthens, GörögországRésztvevőt keres
  • Laiko General Hospital of AthensAthens, GörögországRésztvevőt keres
  • University General Hospital AttikonAthens, GörögországRésztvevőt keres
  • General Hospital Of Thessaloniki PapageorgiouEfkarpia, GörögországRésztvevőt keres
  • University General Hospital of HeraklionHeraklion, GörögországRésztvevőt keres
  • General University Hospital of LarissaLarissa, GörögországRésztvevőt keres
  • General University Hospital Of PatrasPatras, GörögországRésztvevőt keres
  • Hippokration HospitalThessaloniki, GörögországRésztvevőt keres
  • Geniko Nosokomeio Nikaias Peiraia Ag. Panteleimon Geniko Nosokomeio Dytikis Attikis IΝikaia, GörögországRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

To determine the effect of buccal fluasterone on hyperglycemia associated with the diagnosis of endogenous hypercortisolemia (possible Cushing’s syndrome) in patients suffering from impaired glucose tolerance or diabetes mellitus

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. szeptember 14.